Tags

Type your tag names separated by a space and hit enter

Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation.
Pediatr Blood Cancer. 2012 Oct; 59(4):762-4.PB

Abstract

Anti-seizure prophylaxis is routinely utilized during busulfan administration for HSCT. We evaluated the feasibility and efficacy of levetiracetam in children undergoing HSCT. A total of 28 children and young adults received levetiracetam during HSCT and the outcomes and costs were compared to a historical, but similar cohort of 25 patients who had received fosphenytoin. Levetiracetam was well tolerated and was efficacious in preventing seizures. Cost of drug, administration, and monitoring were also similar among the two groups. Due to non-induction of the hepatic cytochrome P450 enzymes, levetiracetam may lead to better dose assurance of busulfan in targeted dose regimens for HSCT.

Authors+Show Affiliations

Division of Pediatric Hematology/Oncology and BMT, Nationwide Children's Hospital, Columbus, Ohio 43205, USA. sandeep.soni@nationwidechildrens.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22378696

Citation

Soni, Sandeep, et al. "Levetiracetam for Busulfan-induced Seizure Prophylaxis in Children Undergoing Hematopoietic Stem Cell Transplantation." Pediatric Blood & Cancer, vol. 59, no. 4, 2012, pp. 762-4.
Soni S, Skeens M, Termuhlen AM, et al. Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2012;59(4):762-4.
Soni, S., Skeens, M., Termuhlen, A. M., Bajwa, R. P., Gross, T. G., & Pai, V. (2012). Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation. Pediatric Blood & Cancer, 59(4), 762-4. https://doi.org/10.1002/pbc.24126
Soni S, et al. Levetiracetam for Busulfan-induced Seizure Prophylaxis in Children Undergoing Hematopoietic Stem Cell Transplantation. Pediatr Blood Cancer. 2012;59(4):762-4. PubMed PMID: 22378696.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation. AU - Soni,Sandeep, AU - Skeens,Micah, AU - Termuhlen,Amanda M, AU - Bajwa,Rajinder P S, AU - Gross,Thomas G, AU - Pai,Vinita, Y1 - 2012/02/29/ PY - 2011/09/19/received PY - 2012/02/09/accepted PY - 2012/3/2/entrez PY - 2012/3/2/pubmed PY - 2012/10/16/medline SP - 762 EP - 4 JF - Pediatric blood & cancer JO - Pediatr Blood Cancer VL - 59 IS - 4 N2 - Anti-seizure prophylaxis is routinely utilized during busulfan administration for HSCT. We evaluated the feasibility and efficacy of levetiracetam in children undergoing HSCT. A total of 28 children and young adults received levetiracetam during HSCT and the outcomes and costs were compared to a historical, but similar cohort of 25 patients who had received fosphenytoin. Levetiracetam was well tolerated and was efficacious in preventing seizures. Cost of drug, administration, and monitoring were also similar among the two groups. Due to non-induction of the hepatic cytochrome P450 enzymes, levetiracetam may lead to better dose assurance of busulfan in targeted dose regimens for HSCT. SN - 1545-5017 UR - https://www.unboundmedicine.com/medline/citation/22378696/Levetiracetam_for_busulfan_induced_seizure_prophylaxis_in_children_undergoing_hematopoietic_stem_cell_transplantation_ L2 - https://doi.org/10.1002/pbc.24126 DB - PRIME DP - Unbound Medicine ER -